CRIS Current Research Information System

POLUZZI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 13.001
NA - Nord America 12.290
EU - Europa 9.999
AF - Africa 817
SA - Sud America 712
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 7
Totale 36.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.106
SG - Singapore 3.521
CN - Cina 3.203
VN - Vietnam 3.144
IT - Italia 2.595
GB - Regno Unito 2.027
DE - Germania 1.542
HK - Hong Kong 1.177
SE - Svezia 845
IN - India 582
FR - Francia 572
BR - Brasile 514
RU - Federazione Russa 446
UA - Ucraina 373
NL - Olanda 351
KR - Corea 332
IE - Irlanda 313
CI - Costa d'Avorio 283
JP - Giappone 282
FI - Finlandia 217
TG - Togo 213
ZA - Sudafrica 167
CA - Canada 115
EE - Estonia 107
PH - Filippine 94
AT - Austria 90
ID - Indonesia 84
AR - Argentina 82
JO - Giordania 82
BE - Belgio 78
TH - Thailandia 73
TR - Turchia 69
PL - Polonia 65
BG - Bulgaria 61
CH - Svizzera 58
ES - Italia 58
BD - Bangladesh 54
MX - Messico 50
IQ - Iraq 45
TW - Taiwan 43
NG - Nigeria 37
AU - Australia 35
PT - Portogallo 34
PK - Pakistan 33
SA - Arabia Saudita 33
SC - Seychelles 32
HR - Croazia 29
UZ - Uzbekistan 28
GR - Grecia 27
CO - Colombia 26
EC - Ecuador 24
IR - Iran 20
LT - Lituania 19
RO - Romania 19
MA - Marocco 18
VE - Venezuela 18
CL - Cile 15
IL - Israele 15
KE - Kenya 15
MY - Malesia 15
PE - Perù 14
CZ - Repubblica Ceca 13
PY - Paraguay 12
DK - Danimarca 11
EG - Egitto 11
LB - Libano 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
NZ - Nuova Zelanda 10
SK - Slovacchia (Repubblica Slovacca) 8
SY - Repubblica araba siriana 7
KZ - Kazakistan 6
RS - Serbia 6
SI - Slovenia 6
DZ - Algeria 5
GH - Ghana 5
NP - Nepal 5
SM - San Marino 5
UY - Uruguay 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
HU - Ungheria 4
JM - Giamaica 4
MT - Malta 4
XK - ???statistics.table.value.countryCode.XK??? 4
CY - Cipro 3
HN - Honduras 3
KH - Cambogia 3
LK - Sri Lanka 3
LY - Libia 3
OM - Oman 3
PA - Panama 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
GA - Gabon 2
Totale 36.832
Salva come PNG Salva come JPEG
Città #
Singapore 2.422
Southend 1.694
Ashburn 1.453
Hong Kong 1.087
Fairfield 914
Chandler 901
Ho Chi Minh City 735
Hefei 728
Santa Clara 661
Dong Ket 595
San Jose 574
Hanoi 549
Bologna 521
Wilmington 460
Frankfurt am Main 452
Princeton 417
Woodbridge 407
Seattle 385
Houston 380
Beijing 372
Ann Arbor 362
Seoul 306
Dublin 303
Cambridge 296
Abidjan 283
Los Angeles 276
Boardman 268
Tokyo 220
Lauterbourg 218
Dallas 216
Lomé 213
Jacksonville 204
Helsinki 179
Milan 160
Rome 146
Westminster 146
Nanjing 143
Council Bluffs 133
Padova 127
Berlin 120
New York 118
Redmond 114
Buffalo 102
Turin 88
Da Nang 86
Saint Petersburg 84
Shenyang 82
Amman 81
Haiphong 81
Redondo Beach 81
Bremen 79
Jinan 78
Medford 78
Shanghai 75
London 72
Bengaluru 69
Brussels 68
San Diego 67
Florence 62
The Dalles 62
São Paulo 61
Munich 59
Mülheim 57
Sofia 56
Guangzhou 55
Jakarta 54
Orem 51
Falkenstein 50
Vienna 50
Nanchang 48
Toronto 48
Falls Church 47
Hebei 47
Chicago 46
Nuremberg 44
Zhengzhou 42
Warsaw 41
Amsterdam 40
Bern 39
Changsha 39
Dearborn 38
Tianjin 38
Biên Hòa 37
Biella 36
Des Moines 36
Phoenix 36
Bangkok 34
Jiaxing 33
Modena 33
Hangzhou 32
Istanbul 32
Secaucus 32
Redwood City 31
Abeokuta 30
Olalla 30
Paris 30
Yubileyny 30
Johannesburg 29
San Francisco 29
Can Tho 28
Totale 23.281
Salva come PNG Salva come JPEG
Nome #
'Use of antipsychotics in children and adolescents: A picture from the ARITMO population-based European cohort study' 767
Leucoencefalopatia Multifocale Progressiva: complicanza dell'immunosoppressione o reazione avversa da farmaci? 565
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 487
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 483
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 349
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 337
Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project 301
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 296
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 295
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 287
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals 283
Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors 281
Farmacoutilizzazione in ospedale: analisi delle variabilità in una realtà regionale 271
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 270
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 269
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 259
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 256
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 255
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 245
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 237
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 234
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 233
Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study 230
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 225
A 3 year survey on the use of antibacterial agents in five Italian hospitals. 223
Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health 220
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 219
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 219
Antibacterial macrolides: a drug class with a complex pharmacological profile 217
Predictors of antipsychotic prescription in a Northern Italian District (Bologna) 215
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 213
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 211
Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy 211
Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement 205
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 205
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 205
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 203
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 201
Association between Paraesthesia and Local Anesthetics: Data Mining of the Public Version of the FDA Adverse Event Reporting System, 197
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 195
Social and clinical descriptors of antipsychotic prescription 194
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 193
Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study 192
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 192
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 191
Deprescribing as a strategy for improving safety of medicines in older people: Clinical and regulatory perspective 191
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 189
Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. 188
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 188
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 187
Prescription patterns of antiepileptic drugs in young women: development of a tool to distinguish between epilepsy and psychiatric disorders 187
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 186
An approach to evaluate appropriateness in the antibacterial therapy in Italian hospitals. 185
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database 185
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 183
Drug-induced Kounis syndrome: A matter of pharmacovigilance 183
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study 182
An update on the first decade of the European centralized procedure: how many innovative drugs? 181
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. 181
Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants 180
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 179
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 179
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 179
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 178
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 177
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 176
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 176
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 174
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 174
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 173
Changes in prevalence and pattern of drug use in a ten years period in Italy. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics 172
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 172
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 171
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 171
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 169
Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics 168
The hERG K+ channel: target and antitarget strategies in drug development. 168
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 167
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 167
Paraesthesia after Local Anaesthetics: An Analysis of Reports to the FDA Adverse Event Reporting System 165
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study 163
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 162
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 162
Predictors of non-adherence with oral bisphosphonates: an Italian retrospective cohort study on administrative databases 161
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 161
La condivisione dei trattamenti farmacologici in psichiatria e la percezione degli effetti avversi ai farmaci antipisicotici da medico, paziente e familiare 160
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 159
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 159
Excipients in medicinal products used in gastroenterology as a possible cause of side effects. 158
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 156
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies 155
Farmaci lassativi e purganti 155
Fattori determinanti nell'utilizzo dei farmaci antipsicotici 155
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 155
Use and Perception of Phytoestrogens in Postmenopausal Women: Result of a Questionnaire-Based Survey 154
Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study 154
Developing a Method To Identify Prescribing Profiles of Antihypertensive Drugs in General Practice. 152
Triptans and serious cardiovascular events: possible safety signals from the FDA Adverse Event Reporting System database 152
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 152
Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy 151
Totale 21.403
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.631
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 322
Totale 99.953
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.190 0 0 0 0 0 0 0 0 0 150 167 873
2021/20223.831 401 121 201 192 318 226 160 267 169 229 919 628
2022/20234.598 505 599 350 549 276 322 171 304 725 189 385 223
2023/20242.067 123 226 227 297 161 209 88 344 46 133 127 86
2024/20256.024 379 780 562 367 933 372 376 259 141 375 313 1.167
2025/202613.231 1.153 1.361 1.309 906 1.512 1.096 2.101 484 2.370 939 0 0
Totale 37.692